Lipocine (NASDAQ:LPCN) Share Price Passes Below 200 Day Moving Average – Here’s What Happened

Lipocine Inc. (NASDAQ:LPCN) shares crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.66 and traded as low as $2.36. Lipocine shares last traded at $2.45, with a volume of 23,102 shares traded.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Weiss Ratings lowered Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Wall Street Zen upgraded shares of Lipocine from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Lipocine currently has a consensus rating of “Reduce” and an average price target of $15.00.

Lipocine Price Performance

The stock has a 50 day moving average price of $2.23 and a two-hundred day moving average price of $3.66. The company has a market capitalization of $20.19 million, a price-to-earnings ratio of -1.37 and a beta of 0.47.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.08. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.21 million. Sell-side analysts forecast that Lipocine Inc. will post -1.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LPCN. Seven Fleet Capital Management LP bought a new stake in shares of Lipocine during the first quarter worth $998,000. Stempoint Capital LP bought a new position in Lipocine in the first quarter valued at about $1,282,000. ADAR1 Capital Management LLC acquired a new stake in Lipocine in the first quarter worth about $185,000. Eversept Partners LP acquired a new stake in Lipocine in the first quarter worth about $2,357,000. Finally, Exome Asset Management LLC bought a new stake in Lipocine during the 1st quarter worth about $486,000. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.